Active Drug Surveillance Program of Ferriprox Use

NCT01838291 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 294

Last updated 2013-04-24

No results posted yet for this study

Summary

Observational, open label, prospective, multi-center, post-marketing drug surveillance program.

Conditions

  • Transfusional Iron Overload

Sponsors & Collaborators

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • Fernando Tricta, MD · ApoPharma

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Cyprus
  • Egypt
  • Oman
  • Saudi Arabia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838291 on ClinicalTrials.gov